• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环 miRNA-320a/b 与 D-二聚体联合检测对深静脉血栓患者的诊断价值。

Combination of Circulating miRNA-320a/b and D-Dimer Improves Diagnostic Accuracy in Deep Vein Thrombosis Patients.

机构信息

Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).

出版信息

Med Sci Monit. 2018 Apr 6;24:2031-2037. doi: 10.12659/msm.906596.

DOI:10.12659/msm.906596
PMID:29622762
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5903311/
Abstract

BACKGROUND D-dimer tests have been widely used to rule-out deep venous thrombosis (DVT), but with low specificity. Circulating microRNAs (miRNAs) are novel promising biomarkers in diverse diseases. The purpose of our study was to identify the diagnostic abilities of circulating miRNA-320a/b and to assess their correlation with plasma D-dimer in DVT and post-thrombotic syndrome (PTS) patients. MATERIAL AND METHODS Plasma samples were taken from 30 DVT patients, 30 PTS patients, and 30 age- and sex-matched healthy volunteers. Quantitative real-time PCR (qPCR) assay and turbidimetric immunoassay were conducted to assess the concentrations of miRNA-320a/b and D-dimer in plasma. RESULTS Circulating miRNA-320a and miRNA-320b were significantly upregulated in DVT patients with fold changes of 1.58 and 1.79, respectively. The receiver operating characteristic (ROC) curve analysis showed area under the curve (AUC) values of 0.70 (95% CI: 0.56-0.83) for miRNA-320a and 0.79 (95% CI: 0.67-0.90) for miRNA-320b. Moreover, plasma levels of miRNA-320b were associated with D-dimer values (r=0.52, 95% CI: 0.19-0.74) in DVT. However, no significant changes in plasma miRNA-320a/b and D-dimer were detected in PTS patients. CONCLUSIONS Compared with controls, circulating miRNA-320a/b was differentially expressed in DVT. Simultaneous detection of miRNA-320a/b with D-dimer may improve diagnostic accuracy of DVT.

摘要

背景 D-二聚体检测已广泛用于排除深静脉血栓形成(DVT),但特异性较低。循环 microRNAs(miRNAs)是多种疾病中有前途的新型生物标志物。本研究的目的是确定循环 miRNA-320a/b 的诊断能力,并评估其与 DVT 和血栓后综合征(PTS)患者血浆 D-二聚体的相关性。

材料和方法 采集 30 例 DVT 患者、30 例 PTS 患者和 30 例年龄和性别匹配的健康志愿者的血浆样本。采用实时定量 PCR(qPCR)和比浊免疫测定法检测血浆中 miRNA-320a/b 和 D-二聚体的浓度。

结果 DVT 患者中循环 miRNA-320a 和 miRNA-320b 显著上调,倍数变化分别为 1.58 和 1.79。受试者工作特征(ROC)曲线分析显示,miRNA-320a 的 AUC 值为 0.70(95%CI:0.56-0.83),miRNA-320b 的 AUC 值为 0.79(95%CI:0.67-0.90)。此外,DVT 患者血浆中 miRNA-320b 水平与 D-二聚体值相关(r=0.52,95%CI:0.19-0.74)。然而,PTS 患者的血浆 miRNA-320a/b 和 D-二聚体无明显变化。

结论 与对照组相比,DVT 患者循环 miRNA-320a/b 表达差异。联合检测 miRNA-320a/b 和 D-二聚体可能提高 DVT 的诊断准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3c5/5903311/9d87dbfe212c/medscimonit-24-2031-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3c5/5903311/2f557aba45cf/medscimonit-24-2031-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3c5/5903311/c991cd0aa536/medscimonit-24-2031-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3c5/5903311/9d87dbfe212c/medscimonit-24-2031-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3c5/5903311/2f557aba45cf/medscimonit-24-2031-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3c5/5903311/c991cd0aa536/medscimonit-24-2031-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3c5/5903311/9d87dbfe212c/medscimonit-24-2031-g003.jpg

相似文献

1
Combination of Circulating miRNA-320a/b and D-Dimer Improves Diagnostic Accuracy in Deep Vein Thrombosis Patients.循环 miRNA-320a/b 与 D-二聚体联合检测对深静脉血栓患者的诊断价值。
Med Sci Monit. 2018 Apr 6;24:2031-2037. doi: 10.12659/msm.906596.
2
Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis.血浆 microRNA 特征在深静脉血栓形成患者中的诊断潜力。
Thromb Haemost. 2016 Aug 1;116(2):328-36. doi: 10.1160/TH16-01-0071. Epub 2016 May 19.
3
Combined use of pretest clinical probability score and latex agglutination D-dimer testing for excluding acute deep vein thrombosis.联合使用检测前临床概率评分和乳胶凝集D - 二聚体检测以排除急性深静脉血栓形成
J Vasc Surg. 2009 Nov;50(5):1099-105. doi: 10.1016/j.jvs.2009.06.059. Epub 2009 Aug 22.
4
D-dimer, other markers of haemostasis activation and soluble adhesion molecules in patients with different clinical probabilities of deep vein thrombosis.不同深静脉血栓临床概率患者的D-二聚体、其他止血激活标志物及可溶性黏附分子
Thromb Res. 2002 Nov 1;108(2-3):107-14. doi: 10.1016/s0049-3848(03)00007-0.
5
Risk factors for deep vein thrombosis after orthopedic surgery and the diagnostic value of D-dimer.骨科手术后深静脉血栓形成的危险因素及D-二聚体的诊断价值
Ann Vasc Surg. 2015;29(4):675-81. doi: 10.1016/j.avsg.2014.12.022. Epub 2015 Feb 26.
6
Admission prevalence of deep vein thrombosis in elderly Chinese patients with hip fracture and a new predictor based on risk factors for thrombosis screening.中国老年髋部骨折患者深静脉血栓形成的入院患病率及基于血栓形成危险因素的新型血栓筛查预测指标
BMC Musculoskelet Disord. 2018 Dec 20;19(1):444. doi: 10.1186/s12891-018-2371-5.
7
Soluble platelet endothelial cell adhesion molecule 1 (sPECAM-1) improves diagnostic accuracy of D-Dimer in patients with suspected deep vein thrombosis (DVT).可溶性血小板内皮细胞黏附分子 1(sPECAM-1)提高了疑似深静脉血栓形成(DVT)患者 D-二聚体的诊断准确性。
J Thromb Thrombolysis. 2020 Aug;50(2):380-385. doi: 10.1007/s11239-020-02087-7.
8
Diagnostic possibilities of specific fibrin(ogen) degradation products in relation to venous thromboembolism.特定纤维蛋白(原)降解产物与静脉血栓栓塞症相关的诊断可能性
Blood Coagul Fibrinolysis. 2013 Apr;24(3):297-304. doi: 10.1097/MBC.0b013e32835bdcbd.
9
Excluding deep venous thrombosis in symptomatic outpatients: is fibrin monomer aid to D-dimer analysis?排除有症状门诊患者的深静脉血栓形成:纤维蛋白单体有助于D-二聚体分析吗?
Blood Coagul Fibrinolysis. 2009 Oct;20(7):546-51. doi: 10.1097/MBC.0b013e32832e0605.
10
Plasma D-dimer is not useful in the prediction of deep vein thrombosis after total knee arthroplasty in patients using rivaroxaban for thromboprophylaxis.在使用利伐沙班进行血栓预防的患者中,血浆 D-二聚体对于全膝关节置换术后深静脉血栓的预测没有帮助。
J Orthop Surg Res. 2018 Jul 11;13(1):173. doi: 10.1186/s13018-018-0883-1.

引用本文的文献

1
Advanced Research in the Pathophysiology of Venous Thromboembolism-Acute Pulmonary Embolism.静脉血栓栓塞症-急性肺栓塞病理生理学的前沿研究
Biomedicines. 2025 Apr 8;13(4):906. doi: 10.3390/biomedicines13040906.
2
Molecular Mechanism of Notch Signaling and Macrophages in Deep Vein Thrombosis: A Comprehensive Review.Notch信号通路与巨噬细胞在深静脉血栓形成中的分子机制:综述
Cell Biochem Biophys. 2025 Apr 25. doi: 10.1007/s12013-025-01761-y.
3
Risk Factors and Clinical Value of Deep Venous Thrombosis After Traumatic Lower Limb Fractures.

本文引用的文献

1
Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma.循环微小RNA检测 panel 作为鉴别丙型肝炎病毒相关肝细胞癌的诊断工具
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):e51-e62. doi: 10.1016/j.clinre.2017.06.004. Epub 2017 Jul 24.
2
Interleukin 37 promotes angiogenesis through TGF-β signaling.白细胞介素 37 通过 TGF-β 信号促进血管生成。
Sci Rep. 2017 Jul 21;7(1):6113. doi: 10.1038/s41598-017-06124-z.
3
Thrombospondin-4 mediates TGF-β-induced angiogenesis.血小板反应蛋白-4介导转化生长因子-β诱导的血管生成。
创伤性下肢骨折后深静脉血栓形成的危险因素及临床价值
J Clin Lab Anal. 2025 Apr;39(8):e70019. doi: 10.1002/jcla.70019. Epub 2025 Mar 28.
4
Impacts of COVID-19 on hemostasis: coagulation abnormalities and management perspectives.2019冠状病毒病对止血的影响:凝血异常及管理观点
Ann Med Surg (Lond). 2024 Jul 2;86(10):5844-5850. doi: 10.1097/MS9.0000000000002237. eCollection 2024 Oct.
5
MicroRNA expression alteration in chronic thromboembolic pulmonary hypertension: A systematic review.慢性血栓栓塞性肺动脉高压中微小RNA表达改变:一项系统评价
Pulm Circ. 2024 Sep 20;14(3):e12443. doi: 10.1002/pul2.12443. eCollection 2024 Jul.
6
A Comparative Analysis of MicroRNA Expression in Mild, Moderate, and Severe COVID-19: Insights from Urine, Serum, and Nasopharyngeal Samples.轻度、中度和重度 COVID-19 患者尿液、血清和鼻咽样本中 microRNA 表达的比较分析。
Biomolecules. 2023 Nov 21;13(12):1681. doi: 10.3390/biom13121681.
7
MiRNAs and Their Role in Venous Thromboembolic Complications.微小RNA及其在静脉血栓栓塞并发症中的作用。
Diagnostics (Basel). 2023 Nov 4;13(21):3383. doi: 10.3390/diagnostics13213383.
8
Evaluation of altered miRNA expression pattern to predict COVID-19 severity.评估改变的微小RNA表达模式以预测新冠病毒疾病的严重程度。
Heliyon. 2023 Feb;9(2):e13388. doi: 10.1016/j.heliyon.2023.e13388. Epub 2023 Feb 1.
9
Depleted miR-125a-5p Causes Vascular Endothelial Cell Dysfunction in Deep Vein Thrombosis by Targeting Angiopoietin 2.miR-125a-5p缺失通过靶向血管生成素2导致深静脉血栓形成中的血管内皮细胞功能障碍。
Indian J Hematol Blood Transfus. 2023 Jan;39(1):116-122. doi: 10.1007/s12288-022-01572-8. Epub 2022 Sep 7.
10
Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic-pharmacodynamic profiles of rivaroxaban.循环 miR-320a-3p 和 miR-483-5p 水平与利伐沙班的药代动力学-药效学特征相关。
Hum Genomics. 2022 Dec 28;16(1):72. doi: 10.1186/s40246-022-00445-5.
Oncogene. 2017 Sep 7;36(36):5189-5198. doi: 10.1038/onc.2017.140. Epub 2017 May 8.
4
Iliac Vein Compression Syndrome (IVCS): An Under-Recognized Risk Factor for Left-Sided Deep Venous Thrombosis (DVT) in Old Hip Fracture Patients.髂静脉受压综合征(IVCS):老年髋部骨折患者左侧深静脉血栓形成(DVT)的一个未被充分认识的危险因素。
Med Sci Monit. 2017 May 1;23:2078-2082. doi: 10.12659/msm.901639.
5
An Uncommon Case of Lower Limb Deep Vein Thrombosis with Multiple Etiological Causes.一例病因多样的下肢深静脉血栓形成罕见病例。
Am J Case Rep. 2017 Mar 28;18:313-316. doi: 10.12659/ajcr.902391.
6
New biomarkers and imaging approaches for the diagnosis of deep venous thrombosis.用于诊断深静脉血栓形成的新型生物标志物和成像方法。
Curr Opin Hematol. 2017 May;24(3):274-281. doi: 10.1097/MOH.0000000000000339.
7
The post-thrombotic syndrome.血栓形成后综合征
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):413-418. doi: 10.1182/asheducation-2016.1.413.
8
Circulating MicroRNAs as Novel Biomarkers of Stenosis Progression in Asymptomatic Carotid Stenosis.循环微小RNA作为无症状性颈动脉狭窄狭窄进展的新型生物标志物
Stroke. 2017 Jan;48(1):10-16. doi: 10.1161/STROKEAHA.116.013650. Epub 2016 Nov 29.
9
Thrombosis, Hypercoagulable States, and Anticoagulants.血栓形成、高凝状态与抗凝剂
Prim Care. 2016 Dec;43(4):619-635. doi: 10.1016/j.pop.2016.07.001.
10
MicroRNA in atherothromobosis: is it useful as a disease marker?动脉粥样硬化血栓形成中的微小RNA:它能否作为一种疾病标志物?
Thromb J. 2016 Oct 4;14(Suppl 1):21. doi: 10.1186/s12959-016-0112-2. eCollection 2016.